Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Market Cap
$526.91M
P/E Ratio
-1.67
1Y Stock Return
-41.15%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.8
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Current Value
$2.421 Year Return
Current Value
$2.421 Year Return
SeekingAlpha
Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed among analysts. Click for my SANA update.
Finnhub
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Yahoo
Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Yahoo
SEATTLE (AP) — Sana Biotechnology Inc. SANA) on Friday reported a loss of $59.9 million in its third quarter. On a per-share basis, the Seattle-based company said it had a loss of 25 cents.
Yahoo
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025Announced increased focus on type 1 diabetes and B-cell mediated
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GIS | -19.68% | $34.85B | -2.91% | 3.78% |
CPB | -17.25% | $12.96B | +7.08% | 3.40% |
PGR | -13.15% | $149.10B | +57.29% | 0.45% |
CME | -12.89% | $82.76B | +9.21% | 1.98% |
LMT | -12.31% | $126.40B | +18.99% | 2.36% |
NOC | -11.83% | $71.54B | +4.23% | 1.60% |
CBOE | -11.33% | $21.46B | +15.84% | 1.11% |
ROL | -10.94% | $23.98B | +23.53% | 1.25% |
TEM | -10.34% | $8.50B | 0.00% | 0.00% |
SAR | -10.17% | - | - | 11.52% |
DTM | -10.11% | $10.01B | +81.71% | 2.87% |
USM | -9.73% | $5.35B | +41.82% | 0.00% |
TPST | -9.12% | $37.75M | -77.59% | 0.00% |
CHD | -8.84% | $27.18B | +19.50% | 1.03% |
VSTA | -8.83% | $204.94M | -39.33% | 0.00% |
CL | -8.41% | $76.48B | +22.25% | 2.12% |
HUSA | -8.28% | $16.69M | -11.56% | 0.00% |
ALL | -8.26% | $52.06B | +45.67% | 1.85% |
CYCN | -7.42% | $4.77M | -16.19% | 0.00% |
PEP | -6.93% | $215.02B | -6.60% | 3.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ARWR | 38.91% | $2.31B | -34.44% | 0.00% |
KYMR | 38.67% | $2.77B | +125.95% | 0.00% |
ALEC | 37.68% | $377.04M | -19.46% | 0.00% |
WDFC | 36.90% | $3.79B | +20.32% | 1.26% |
PD | 36.74% | $1.74B | -12.09% | 0.00% |
PRTA | 36.51% | $756.01M | -56.52% | 0.00% |
RGNX | 36.42% | $473.65M | -51.96% | 0.00% |
GBIO | 36.39% | $92.84M | +20.87% | 0.00% |
FATE | 36.33% | $248.29M | -11.02% | 0.00% |
NNOX | 35.93% | $332.87M | -7.63% | 0.00% |
ATRO | 35.59% | $575.48M | +5.29% | 0.00% |
ARQT | 35.57% | $1.18B | +433.86% | 0.00% |
BXC | 35.55% | $1.01B | +40.40% | 0.00% |
CDXS | 35.33% | $345.86M | +121.35% | 0.00% |
JELD | 35.12% | $859.74M | -34.45% | 0.00% |
CRNX | 34.89% | $5.12B | +84.27% | 0.00% |
EDIT | 34.88% | $204.72M | -75.49% | 0.00% |
ABCL | 34.74% | $800.44M | -37.56% | 0.00% |
SATS | 34.16% | $6.59B | +129.45% | 0.00% |
KELYA | 34.00% | $504.23M | -32.54% | 2.14% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYD | <0.01% | $364.46M | -2.94% | 4.26% |
KSPI | -0.01% | $20.86B | +18.06% | 3.37% |
MCD | -0.06% | $208.34B | +3.66% | 2.30% |
LUMO | -0.12% | $37.45M | +41.97% | 0.00% |
TTE | -0.13% | $138.45B | -11.95% | 5.50% |
TPL | 0.17% | $32.63B | +163.13% | 0.64% |
ASPS | 0.18% | $22.36M | -80.26% | 0.00% |
BCAN | 0.18% | $72.87M | -99.75% | 0.00% |
VRSK | -0.21% | $39.77B | +17.45% | 0.53% |
LNG | -0.26% | $49.37B | +24.99% | 0.82% |
AMED | 0.37% | $2.95B | -3.95% | 0.00% |
SYPR | -0.37% | $32.23M | -26.32% | 0.00% |
ASUR | -0.43% | $233.14M | +12.13% | 0.00% |
STKL | 0.44% | $894.47M | +55.49% | 0.00% |
KRRO | -0.44% | $436.84M | +20.68% | 0.00% |
IMRN | 0.47% | $10.31M | -5.04% | 0.00% |
STG | -0.49% | $35.67M | +7.92% | 0.00% |
SBUX | 0.49% | $111.45B | -5.15% | 2.37% |
DRD | -0.49% | $854.61M | +13.63% | 2.30% |
VITL | 0.50% | $1.32B | +142.79% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -35.68% | $388.04M | 1.43% |
VIXY | -19.51% | $195.31M | 0.85% |
UUP | -15.06% | $309.25M | 0.77% |
USDU | -14.33% | $201.97M | 0.5% |
TAIL | -11.99% | $67.98M | 0.59% |
BSCO | -11.12% | $2.35B | 0.1% |
TPMN | -9.51% | $40.60M | 0.65% |
MINT | -9.13% | $11.62B | 0.35% |
SGOV | -8.69% | $27.53B | 0.09% |
CTA | -8.31% | $350.27M | 0.78% |
SOYB | -7.84% | $27.32M | 0.22% |
UNG | -7.58% | $908.80M | 1.06% |
CORN | -7.10% | $61.12M | 0.2% |
CSHI | -6.99% | $482.85M | 0.38% |
XBIL | -6.91% | $637.70M | 0.15% |
TBIL | -6.83% | $4.38B | 0.15% |
EQLS | -6.52% | $76.08M | 1% |
WEAT | -6.35% | $120.27M | 0.28% |
BILZ | -5.61% | $563.02M | 0.14% |
XHLF | -5.49% | $874.27M | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CCOR | 0.07% | $109.04M | 1.18% |
IYK | 0.12% | $1.30B | 0.4% |
AGZD | -0.31% | $142.76M | 0.23% |
DBE | 0.66% | $50.13M | 0.77% |
HDRO | 0.87% | $164.26M | 0.3% |
XONE | 0.91% | $548.88M | 0.03% |
DUSB | 0.98% | $797.63M | 0.15% |
IBD | 1.03% | $330.68M | 0.44% |
CLOI | 1.11% | $715.40M | 0.4% |
FTSD | 1.16% | $171.68M | 0.25% |
FTGC | 1.20% | $2.17B | 1.02% |
BCD | 1.27% | $245.02M | 0.3% |
DBO | 1.29% | $217.57M | 0.77% |
KRBN | 1.36% | $242.47M | 0.85% |
FLRN | -1.56% | $2.33B | 0.15% |
ULST | 1.58% | $535.47M | 0.2% |
USCI | 1.62% | $185.47M | 1.07% |
BOXX | -1.64% | $4.43B | 0.1949% |
DBA | -2.17% | $755.88M | 0.93% |
BCI | 2.17% | $1.20B | 0.26% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 49.81% | $70.59M | 0.5% |
XBI | 47.50% | $6.58B | 0.35% |
EFAA | 46.36% | $117.38M | 0% |
ARKG | 46.18% | $1.13B | 0.75% |
PTH | 44.35% | $143.31M | 0.6% |
IWC | 42.70% | $933.99M | 0.6% |
RSPA | 42.43% | $273.87M | 0% |
XPH | 41.31% | $157.87M | 0.35% |
IBB | 41.16% | $6.66B | 0.45% |
IWO | 40.05% | $12.56B | 0.24% |
IWM | 39.73% | $75.73B | 0.19% |
ROBT | 39.70% | $441.35M | 0.65% |
VTWO | 39.58% | $12.38B | 0.1% |
PBE | 39.40% | $258.53M | 0.58% |
FNY | 39.16% | $372.31M | 0.7% |
NUSC | 38.89% | $1.27B | 0.31% |
KOMP | 38.86% | $2.09B | 0.2% |
ISCG | 38.80% | $640.00M | 0.06% |
ARKK | 38.76% | $6.28B | 0.75% |
ESML | 38.70% | $1.90B | 0.17% |